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Poor solubility of new chemical entities (NCEs) is a major bottleneck in the pharmaceutical industry which 
typically leads to poor drug bioavailability and efficacy. Nanotechnologies offer an interesting route to improve 
the apparent solubility and dissolution rate of pharmaceutical drugs, and processes such as nano-spray drying 
and supercritical CO2-assisted spray drying (SASD) provide a route to engineer and produce solid drug nano-
particles. However, dried nanoparticles often show poor rheological properties (e.g. flowability, tabletability) 
and their isolation using these methods is typically inefficient and leads to poor collection yields. The work 
presented herein demonstrates a novel production and isolation method for drug nanoparticles using a ‘top spray 
dynamic bed coating’ process, which uses CO2 spray as the fluidizing gas. Nanoparticles of three BCS class II 
Active Pharmaceutical Ingredients (APIs), namely carbamazepine (CBZ), ketoprofen (KET) and risperidone (RIS), 
were produced and successfully coated onto micron-sized microcrystalline cellulose (MCC) particles. The size 
distribution of the API nanoparticles was in the range of 90–490 nm. The stable forms of CBZ (form III), KET 
(form I), and the metastable form of RIS (form B) were produced and coated onto MCC carrier microparticles. All 
the isolated solids presented optimal rheological properties along with a 2–6 fold improvement in the dissolution 
rate of the corresponding APIs. Hence, the ‘top spray dynamic bed coater’ developed in this work demonstrates to 
be an efficient approach to produce and coat API nanoparticles onto carrier particles with optimal rheological 
properties and improved dissolution.   
1. Introduction 
The emerging use of combinatorial chemistry in drug development 
has resulted in new drug candidates with high lipophilicity, high mo-
lecular weight and low water solubility. The majority of the failures in 
new drug development have been attributed to low water solubility of 
the drugs which leads to poor bioavailability and results in sub-optimal 
drug delivery/efficacy (Kalepu and Nekkanti, 2015). Nearly 40% of the 
top 200 oral drugs marketed in the USA and Europe, and 90% of the new 
chemical entities which are in the drug development pipeline in the 
pharmaceutical industry are poorly water soluble (Tan et al., 2017). 
Thus, low solubility of drugs at the site of administration leads to low 
quantity of available diffusion, leading to insufficient drug concentra-
tion at the site of action and in-vivo failure (Siepmann and Siepmann, 
2013). Modified formulation strategies have been gaining traction in the 
pharmaceutical arena due to their ability to improve the dissolution of 
BCS (Biopharmaceutical Classification System) Class II and IV drugs. 
Some of the available drug delivery technologies with a potential to 
circumvent the solubility, dissolution rate and bioavailability of the 
poorly soluble drug includes amorphous solid dispersions, crystal engi-
neering, inclusion complexes, lipid based formulations and nano-
particles (Loftsson and Brewster, 2010; Alam et al., 2012; Müllertz et al., 
2010; Rabinow, 2004). 
In the recent years, nanosizing has emerged as an important drug 
delivery platform approach for the commercial development of the 
poorly soluble pharmaceutical drugs. Nanoparticles can be produced 
either by top-down or bottom-up approaches. Top-down methods 
involve the breakage of large particles into smaller ones, which is 
typically achieved by milling or high pressure homogenization. Both of 
these top down techniques have been meticulously studied and dis-
cussed in the literature by Müller in his reviews (Keck and Müller, 2006; 
Shegokar and Müller, 2010; Müller et al., 2001), and by other authors 
(Hanafy et al., 2007; Jia et al., 2003; Jinno et al., 2006; Onoue et al., 
2013). In contrast to top-down methods, bottom-up methods generate 
nanoparticles by building them from drug molecules in solution, which 
typically is achieved by controlled precipitation (antisolvent 
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precipitation, sonoprecipitation etc.) and solvent removal (spray-drying, 
electrospraying etc.) techniques (Chan and Kwok, 2011). Generally, the 
production of nanoparticles using top-down techniques requires high 
energy, which generally leads to contamination if a milling method is 
applied. While the bottom-up approach possess advantages such as low 
energy requirements and lower cost, these methods typically use organic 
solvents which are difficult to remove from the product (Miyazaki et al., 
2016). 
Nanosizing formulation techniques generate drug nanocrystals with 
a mean particle size between 1 and 1000 nm. Nanoparticles vary 
distinctly in their properties from micronized drug particles due to their 
small particles size. Similarly to other colloidal systems, drug nano-
crystals tend to reduce their energy state by forming larger agglomerates 
or crystal growth (Möschwitzer, 2013). Particle agglomeration, recrys-
tallisation and amorphization are the main instability factor for the drug 
nanoparticles. Thus, they are often stabilized with surfactants, stabi-
lizers or combinations thereof (Gigliobianco et al., 2018). These insta-
bility factors often lead to inefficient formulation strategies for the drug 
products and impact significantly their rheological properties due to 
poor flowability and compressibility. 
Carbon dioxide (CO2) is being used in the pharmaceutical production 
as a replacement to organic solvents because it is abundant, nontoxic, 
inexpensive, and suitable for development of environmentally friendly 
processes (Long et al., 2019a, 2019b). Supercritical CO2 (scCO2) has 
attracted attention of the pharmaceutical researchers in the last few 
decades due to its ability to manufacture fine drug particles in amor-
phous or crystalline form (Long et al., 2019b; Matos et al., 2020; Li et al., 
2017). There are various particle engineering techniques which use 
scCO2 either as a solvent (e.g. RESS, RESOLV, RESSAS) (Leeke et al., 
2014; Sun et al., 2005; Türk, 2009), an antisolvent (e.g. SAS, GAS) (Long 
et al., 2019a; Gallagher et al., 1989; Marr and Gamse, 2000), or an at-
omization enhancer (e.g. SASD, SAA, PGSS) (Long et al., 2019b; 
Reverchon et al., 2003; Bahrami and Ranjbarian, 2007). Compared to 
most supercritical CO2-based techniques, SASD is further favored for the 
production of spray dried micro- and nanoparticles, as it restrains the 
high-pressure into a small mixing chamber/nozzle and has the ability to 
operate in continuous mode, which is the new stepping stone in the 
pharmaceutical industry. The main benefits of the SASD process is as 
follows (Arpagaus et al., 2017; Padrela et al., 2018):  
• Conversion of liquid to powder in one step  
• Nano/microparticle generation at atmospheric pressure  
• Control of particle size and solid form (amorphous/crystalline form)  
• Scale-up capability  
• Process simplicity with ease of operation 
The SAS process has been used in combination with a fluidized bed to 
coat drug nanoparticles onto micron-sized carrier particles by Li et al., 
(Li et al., 2017). Naringin was dissolved in either methanol, ethanol or 
acetone, and sprayed onto fluidized carrier particles under high pres-
sure. This resulted in amorphous naringin nanoparticles (100–200 nm) 
coated onto fluidized carrier particles with a drug loading of 2.5% and 
processing yield between 44 and 99%. Since the process was under high 
pressure, scalability would be an issue thereby restricting its potential 
use in an industrial environment. Leeke et al., reported on the combi-
nation of the RESS process with a fluidized bed to coat organic molecules 
Fig. 1. Chemical structures of the carrier material, solvent and APIs used in this work.  
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onto microcrystalline cellulose (MCC) particles (Leeke et al., 2014). 
These authors successfully coated 30 nm nanoparticles onto MCC with a 
loading of < 1% and processing yield between 14 and 74%. Low loading 
is related to the typically low solubility of organic molecule in scCO2 and 
this is one of the main reasons that limits the applicability of RESS for 
pharmaceutical production. Hence, there is a need for new processes 
that provide high processing yields with high drug loadings, and that are 
able to operate at ambient pressure. 
The work presented in this paper shows a novel top spray dynamic 
bed coating method to capture/coat API nanoparticles onto micron- 
sized carrier particles with minimum use of stabilizers. Three BCS 
class II APIs, namely carbamazepine (CBZ), ketoprofen (KET), and ris-
peridone (RIS) were selected as model systems for the proof of concept 
of this method, while microcrystalline cellulose (MCC, PH102) was used 
as carrier material. All the experiments were performed at the same API 
concentration, temperature, pressure, solution and CO2 flow rate for an 
efficient comparison of the data. Two drug loadings of 10% and 20% 
were used, as previous studies have only reported drug loadings of <
5%. These drug loadings are based on the fact that the API loading in 
most of the direct compression tablet does not exceeds 30% because of 
the poor processability (Chen et al., 2019; Jivraj, Martini, and Thomson, 
2000). The API-MCC composite samples produced were analyzed to 
determine the exact API loading, processing yield, nanoparticle size and 
solid form. Further the isolated solids were assessed for their flowability 
properties and the improvement in the dissolution rate of the APIs, while 
the tablets prepared of the API-MCC composite were tested for tablet-
ability, compressibility and compactability. 
2. Experimental section 
2.1. Materials 
Methanol (MeOH, >99.9%) and sodium dodecyl sulfate (SDS, 
>99.9% pure) were supplied by Sigma-Aldrich and used as-received. 
Carbamazepine (CBZ, >98% pure, CCDC CBMZPN01) and Risperidone 
(RIS, >98% pure, CCDC WASTEP) were supplied by Kemprotec and used 
as-received. Ketoprofen (KET, >98% pure, CCDC KEMRUP) were kindly 
offered by Clarochem and used as-received. Microcrystalline cellulose 
(MCC) (MW: 36000 g/mol) was kindly offered by FMC International and 
was used as-received. Liquid carbon dioxide (99.98%) was supplied by 
BOC (Ireland). Fig. 1 provides the molecular structures of the carrier 
particles (MCC), the solvent (MeOH) and the APIs (CBZ, KET and RIS) 
used in this study. 
2.2. API solution preparation 
For the production and isolation of API nanoparticles using a top 
spray dynamic bed coating process, CBZ, KET and RIS were dissolved in 
40 mL of methanol (50 mg/mL) using an ultrasonic bath until a clear 
solution is obtained. In the case of CBZ, 10% w/w (5 mg/mL) of the 
additive SDS was added to the CBZ methanol solution to to favour the 
formation of the stable polymorphic form III of CBZ (Padrelaet al., 2017; 
Long et al., 2019b). The solutions were then filtered using 0.2 µm nylon 
syringe filter (Whatman Inc., Florham Park, NJ) to remove any undis-
solved impurity. 
2.3. Production and isolation of API nanoparticles using top spray 
dynamic bed coating 
Fig. 2 presents a schematic of the top spray dynamic bed coating 
process with an enlarged view of the drying chamber consisting of co- 
axial nozzle at the top, carrier particle holder in the middle that holds 
the carrier particles (MCC – Microcrystalline Cellulose) and CO2 outlet 
at the bottom part of the chamber. The primary spray drying apparatus 
shown in Fig. 2B consists of three main parts. The first part is the high- 
pressure small-volume stainless steel nozzle, where mixing between the 
scCO2 (supercritical CO2) and the API solution occurs. The mixing vol-
ume in the coaxial nozzle is 0.1 cm3. The second part is a combination of 
the drying and coating (isolation of API nanoparticles) chamber which is 
a 6000 cm3 vessel surrounded by a heating rope, which facilitates the 
drying of the solvent once atomized. The final part is the CO2 and solvent 
vapour escape, which consists of a silicon tube extending from the 
opening at the bottom of the drying chamber into the water container to 
bubble out the escaping gas. 
Nanoparticle particle isolation was facilitated using a partially open 
steel mesh as presented in Fig. 2B. Steel openings are 5 cm × 1 cm wide 
with a pore size of 40 µm. The pore size of the mesh is 3 times smaller the 
size of the carrier material used (MCC, average size is 150 µm). There-
fore, the MCC particles could pass through the mesh, hence limiting any 
free nanoparticles and the excess gas to pass through the mesh. The 
desired amount of MCC particles is uniformly spread on the covered part 
of the mesh. The mesh was placed at a distance of 15 cm away from the 
nozzle for an efficient coating and yield. Due to the momentum of CO2 
and N2 (drying gas fed from the top), the static bed of the MCC particles 
on the covered part of the mesh transformed into a dynamic bed. This 
random motion of MCC particles also provided some elevation to the 
MCC particles, thereby helping these to capture the API nanoparticles 
sprayed from the top. 
Fig. 2. Schematic representation of (A) top spray dynamic bed coating process, (B) enlarged view of the drying chamber consisting of co-axial nozzle at the top, 
carrier particle holder in the middle and CO2 outlet at the bottom part of the chamber. 
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During the experiments CO2 was compressed to 100 bar using a SFE 
process Dose HPP 400-C pump. The nozzle was maintained at 50⁰ C by 
using heating resistors in close proximity to the nozzle. Each API 
methanol solution was pumped at a flow rate of 0.4 mL/min to the high- 
pressure nozzle using an Agilent technologies 1260 Infinity II pump, 
where it was mixed with the supercritical CO2. After the solution was 
passed through the nozzle, the supercritical CO2 was depressurised and 
any residual solvent was evaporated during the spray-drying step pass-
ing through the vent at the bottom of the chamber. The process variables 
used in this study were established based on the previous study from the 
group by Barry et al., (Long et al., 2019b). They discovered that using 10 
wt% SDS in CBZ solution results in the controlled nucleation of the 
stable form (Form III) of carbamazepine. Further, it was reported that 
carbamazepine methanol solutions with a concentration of 50 mg/mL 
resulted in the formation of crystalline carbamazepine using the SASD 
method, as compared to 17 mg/mL solution concentrations which 
resulted in the formation of amorphous carbamazepine. In addition, 
carbamazepine Form III was obtained when the carbamazepine solution 
flow rate of 0.4 mL/min in comparison to 0.1 mL/min solution flow rate 
resulting in the formation of mixture of polymorphs. Those authors also 
suggested that CO2 pressure did not greatly impact the polymorphic 
outcome. Therefore, we have used similar processing conditions for the 
experimental runs performed in this study i.e. API concentration of 50 
mg/mL, API flow rate of 0.4 mL/min, CO2 pressure of 100 bar and SDS 
concentration of 10 wt% in the case of carbamazepine. Further, the 
authors also performed a preliminary Design of Experiments (DOE) 
study to fix the API loading to 10% and 20%. 
During the API nanoparticle isolation step, the MCC particles were 
placed on the partially open mesh and were fluidized using CO2 and/or 
N2 (four bar) nitrogen (also acted as drying gases). The nanoparticle 
spraying process was initiated only after the fluidization of the MCC 
particles. Upon completion of spraying, the CO2 flow was stopped while 
N2 flow was continued for another 15 min to dry any residual solvent. 
The amount of MCC was adjusted to achieve 10% (18 g of MCC) and 
20% (8 g of MCC) loading of API nanoparticles onto the MCC carrier 
particles. Each experiment was performed in triplicate to ensure the 
reproducibility of the process. The samples were harvested and stored in 
a desiccator prior to characterization to prevent exposure to humidity to 
minimize polymorphic conversions over time. The API loading is 
calculated according to the Eq. (1). 
API loading (%w/w) =
(mass of API sprayed)
(mass of API sprayed) + (mass of excipient)
× 100
(1)  
2.4. Solid state characterisation of the API-MCC composites 
2.4.1. API solid-state form determination 
The solid state/polymorphic form of each API in the isolated API- 
MCC composite solid particles was determined using Powder X-ray 
Diffraction (PXRD) technique. Diffractograms were recorded on a 
PANalytical Empyrean diffractometer using a Cu radiation source (λ =
1.541 nm) at 40 mA and 40 kV. Scans were performed between 5 and 
35◦ 2θ at a scan rate of 0.013◦ 2θ/min. 
2.4.2. API nanocrystal habit determination 
The habit of the isolated API-MCC composite solid particles was 
examined using scanning electron microscopy (SEM), Hitachi SU-70 
system operating at 10 kV. Samples were mounted onto aluminum 
stubs with double-sided carbon tape. Samples were gold coated (S150B, 
Edward) and the surface appearances of the isolated API-MCC composite 
solids were compared. 
2.4.3. Yield calculation 
Processing yield was determined using Eq. (2). 
Yield % =
mass of API coated onto MCC
mass of API sprayed
× 100 (2) 
The amount of API coated onto MCC was determined by dissolving a 
pre-weighed amount of API-MCC composite in 1 L of deionised water. 
The amount of API-MCC composite particles was determined based on 
the API loading, so that the final solution concentration was 20 mg/mL. 
The solution was stirred at 400 rpm for 12 hr in a water bath maintained 
at a constant temperature of 37 ± 0.5⁰C. An aliquot (1 mL of the solu-
tion) was drawn using a syringe and filtered using 0.2 µm Nylon syringe 
filter. Both the syringe and the filter were heated at 5⁰C above the water 
bath temperature to avoid API precipitation. The aliquot was analysed 
using UV spectrophotometer at absorption maximum of 285 nm for CBZ, 
276.5 nm for RIS and 216 nm for KET. The solution concentration was 
then determined using a calibration plot of the API determined at the 
respective wavelength, within a concentration range of 0.5 mg/L to 40 
mg/L. The API concentration was then converted to the amount of API 
present in API-MCC composite, which then was used to determine the 
processing yield for the batch. A minimum of three samples were drawn 
from one batch of API-MCC composites to access the content homoge-
neity as well as reproducibility of the results. 
2.4.4. Particle size distribution analysis of API nanoparticles 
The size of the API nanoparticles attached onto MCC particles was 
measured from the respective SEM micrographs using the ‘measuring’ 
tool of ‘Adobe Acrobat Reader DC’. A minimum of 150 nanoparticles 
were measured for each sample. The average nanoparticle size and 
standard deviation were determined by averaging all the measurements 
and calculating standard deviations, respectively. 
2.4.5. True density measurement 
True density of the samples was measured at ambient temperature 
using the Accupyc II gas displacement pycnometry system (Micro-
mertics®, Nocross, GA, USA) based on USP 699 standard procedure. 
Helium was purged into the sample chamber to determine its volume. 
True density is the mass of a substance divided by its volume, excluding 
open and closed pores. 
2.4.6. Precompression studies of the API-MCC composites 
Prior to the compression of API-MCC composites into tablets, the 
flow properties of the composites were assessed to check its suitability 
for compression. In order to access the flow properties of API-MCC 
composites, the compressibility index and Hausner’s ratios were adop-
ted. The compressibility index and the Hausner ratio are determined by 
measuring both the bulk volume and the tapped volume of a powder 
(Luner et al., 2001; Aulton, 1988). The compressibility index and the 
Hausner ratio are calculated according to Eq. (3) and Eq. (4) 
respectively. 
Compressibility Index = 1 − (
V0 − Vf
V0





A Freeman Technology FT4 Rheometer was used to calculate the 
compressibility index of API-MCC composite powder. The compress-
ibility measurement was performed by applying an increasing level of 
compression force with a vented piston to a conditioned powder and 
measuring the change in volume as a function of applied load. The 
Vented Piston ensures that air trapped within the powder is able to 
readily escape, allowing for precise definition of compressibility which 
is expressed as a percentage change in volume for a given applied 
normal stress. The experiments and calculations were performed in 
triplicate. 
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2.4.7. Tableting of API-MCC composite 
A Gamlen R-series compaction simulator (Gamlen tableting limited, 
UK) was used to compact the API-MCC composite particles. Samples of 
~ 100 mg were tableted using flat-face cylindrical 6 mm punch and die 
with 60 mm/min punch speed and 200 Hz graph sampling rate. Samples 
were compressed under different compaction pressures of 1–5 kN to 
meticulously understand the compaction behaviour of 10% and 20% 
loaded API-MCC composite particles. Powder mechanical properties 
were assessed by determining their tabletability, compactability and 
compressibility. 
2.4.7.1. Tensile strength. Tensile strength of tablets was calculated using 
Fell-Newton equation (Eq. (5)): 
σ = 2FπDt (5)  
where, σ is the tensile strength of the tablets (MPa), F is the tablet dia-
metrical breaking force (N), D is the diameter (m) and t is the thickness 
(m) of the tablet which were measured at once using a PharmaTest 
hardness tester. The diametral breaking force was also measured using 
the PharmaTest hardness tester. 
2.4.7.2. Tablet porosity. Tablet porosity was calculated using Eq. (6): 




where, ρapp is apparent density and ρtrue is the true density (g/cm3). 
Apparent density was calculated by dividing the weight of each tablet by 
its volume which was calculated by measuring the dimensions of each 
tablet using PharmaTest hardness tester. True density was calculated as 
mentioned in Section 2.4.5. 
2.4.7.3. Tabletability. The ability of the material to form compacts with 
a certain tensile strength under the applied compaction pressure is 
called tabletability. It is usually represented using a graph of tensile 
strength as a function of compaction pressure. The linear correlation 
between tensile strength and compaction pressure of the tablet proposed 
by Newton et al., (Newton et al., 1971) is as follows (Eq. (7)): 
σt = CpP + b (7)  
where, Cp is the tabletability parameter, P is the compaction pressure 
and b is a constant. 
2.4.7.4. Compactability. The graph of tensile strength as a function of 
tablet porosity helps to understand the compactibility of the material. A 
mathematical representation of compactability is provided by the 
Ryshkewitch-Duckworth equation (Eq. (8)) (Ryshkewitch, 1953). 
σt = σt0e− bP (8)  
where, σt and σt0 are tablets tensile strength (MPa) and tablet tensile 
strength at zero porosity (MPa), respectively. P is tablet porosity and b is 
an empirical constant representing bonding capacity. Steendam and 
Lerk explained that higher b value represents stronger bonding capacity 
of primary particles (Steendam and Lerk, 1998). 
2.4.7.5. Compressibility. Compressibility of the API nanoparticles 
coated onto MCC particles was assessed using Heckle model. Heckle 
model explores the porosity reduction upon applied compression pres-
sure according to Eq. (9). 





= k.P + A (9)  
where, ε is tablet density, D is the relative density of the tablets, k is the 
Heckel coefficient, P is the applied compression pressure and A is the 
intercept. Reciprocal of the Heckle coefficient results in yield pressure 
(Py). High k and low Py values are indication of more compressible 
powder. 
2.4.8. In-vitro drug release studies 
The dissolution of powder samples was performed under sink con-
ditions with a maximum CBZ solution concentration, [CBZ]max, of 20 
mg/L, KET solution concentration, [KET]max, of 15 mg/L, and RIS so-
lution concentration, [RIS]max, of 15 mg/L. Dissolution was carried out 
using a PHARMATEST PTWS 120D dissolution test system, USP type II 
(paddle) apparatus. Dissolutions were performed in 1000 mL deionised 
water at 37 ± 1 ◦C at a paddle rotation of 100 rpm. One mL aliquots were 
withdrawn at predetermined time intervals (1, 3, 5, 10, 15, 30, 45 and 
60 min) and filtered by Whatman Nylon 13 mm filters of 0.2 μm pore 
size before being analysed by UV spectrophotometry. The API absorp-
tion maximum (as mentioned in Section 2.4.3) was used to quantify the 
amount of API dissolved. Further, dissolution curve fitting was achieved 
using Korsmeyer-Peppas model. Korsmeyer and Peppas put forth a 
simple relationship that describes the drug release from a polymeric 
system and type of dissolution (Eq. (10)). 
F = Ktn (10)  
where, K is Korsmeyer release rate constant and n is the drug release 
exponent. 
3. Results and discussion 
Nanoparticles of carbamazepine (CBZ), risperidone (RIS) and keto-
profen (KET) were successfully produced and coated onto micron-sized 
MCC particles using top spray dynamic bed coating process. 
Table 1 presents the processing yields achieved for the experiments 
where 10% and 20% loadings of each API (e.g. CBZ, RIS, KET) onto MCC 
were used. For each API, experiments were performed in triplicate for 
each loading. Processing yields achieved for CBZ and RIS were in the 
range of 61–76%, and for KET in the range of 49–89%. The processing 
Table 1 
Summary of the average particle size (nm), polymorphic form, and yields (%) 
achieved from the nanoparticle isolation experiments performed using top-spray 
dynamic bed coating process for carbamazepine (CBZ), risperidone (RIS) and 
ketoprofen (KET) using microcrystalline cellulose (MCC) as carrier particles. SD: 
standard deviation.  
10% Loading 
API Run Average particle size (nm) ±
SD 
Polymorphism Yield achieved 
(%) 
CBZ R1 180 ± 52 FIII 75 ± 0.7 
R2 196 ± 89 FIII 61 ± 1.3 
R3 126 ± 43 FIII 73 ± 0.7 
RIS R1 360 ± 90 Form B 76 ± 2.9 
R2 316 ± 68 Form B 67 ± 6.0 
R3 345 ± 93 Form B 62 ± 10 
KET R1 490 ± 160 FI 58 ± 3.7 
R2 380 ± 70 FI 62 ± 1.7 
R3 380 ± 75 FI 89 ± 2.6  
20% Loading 
API Run Average particle size (nm) ±
SD 
Polymorphism Yield achieved 
(%) 
CBZ R1 111 ± 56 FIII 73 ± 2.2 
R2 126 ± 59 FIII 71 ± 2.0 
R3 90 ± 28 FIII 62 ± 1.3 
RIS R1 340 ± 75 Form B 76 ± 1.8 
R2 307 ± 77 Form B 72 ± 6.0 
R3 286 ± 69 Form B 70 ± 6.0 
KET R1 460 ± 280 FI 49 ± 3.2 
R2 310 ± 80 FI 79 ± 9.2 
R3 325 ± 85 FI 77 ± 0.8  
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yields achieved in this work were 10–20 fold higher than the yields 
typically achieved using nano spray dryers equipped with fluidized bed 
coater (Li et al., 2017; Matos et al., 2020, 2018) or wurster coater (Leeke 
et al., 2014), where the yields have been reported to be between 1% and 
4%. 
Fig. 3 presents the PXRD patterns of the isolated API-MCC composite 
samples at different drug loadings. The stable forms of CBZ (Form III) 
and KET (Form I) were obtained at both 10% and 20% loadings, whereas 
the metastable form of RIS (Form B) was obtained. Three different 
batches of each API at each loading generated similar PXRD results 
confirming the robustness and reproducibility of the top spray dynamic 
bed coating process. The intensity of the PXRD peaks is small for both 
loading samples, particularly for 10% loading. This is because for 10% 
loading samples the yield was around 50–60%, therefore the real 
loading is around 5–6% (10% of the yield achieved). This allowed the 
authors to work at a lower detection limit of the PXRD instrument. Also, 
since the major fraction of all the samples produced corresponded to 
MCC, the broad peaks of MCC in the PXRD patterns are clearly visible for 
each sample. 
Fig. 4 presents the SEM micrographs of the solids isolated after the 
experiments at 10% and 20% loadings. A summary of the average par-
ticle size distributions along with standard deviations is also reported in 
Table 1. The SEM micrographs in Fig. 4 confirm the uniform coating of 
API nanoparticles onto the micron-sized MCC carrier particles. The 
average size of CBZ nanoparticles was in the range of 90–200 nm, for RIS 
was 280–350 nm, and for KET was 300–500 nm. The process parameters 
such as pressure, temperature, solution concentration, CO2 flow rate and 
nozzle size were kept constant for each experiment, emphasising on the 
similar size and number of droplets formed during each experiment. 
Hence, the generation of nanoparticles was not only governed by the 
process parameters but also by the different nucleation and growth 
properties of the APIs. From the particle size results obtained it is 
evident that the KET is a fast-growing API, while CBZ is a slow-growing 
API and RIS is a moderately-growing API. 
The flowability of a powder is of critical importance in the produc-
tion of pharmaceutical dosage forms, in order to avoid high dose vari-
ation due to irregular feed and filling of tablet dies. Three flow 
measurements namely, the angle of response, compressibility index and 
Hausner’s ratio can be employed to assess the flowability of a powder 
(Fahmy and Kassem, 2008). In this work, the compressibility index and 
Hausner’s ratio was used to evaluate the flow properties of the API-MCC 
composites. The compressibility index has also been proposed as an 
indirect measure of bulk density, shape and size, surface area, moisture 
content and material cohesiveness and these can influence the 
compressibility index of a material (Brittain, 1995). Fig. 5 presents the 
powder compressibility index of the microcrystalline cellulose, 10% and 
20% loaded API-MCC composite powder, repeated for three different 
batches. Considering the standard deviation of all powders, the 
compressibility index is similar at all applied stress. This signifies that 
the coating of API nanoparticles onto MCC particles retained the flow 
behavior of MCC (PH102) particles. Flowability of MCC PH102 is one of 
critical benchmark manufacturing parameters in the pharmaceutical 
industry (Chen et al., 2019). 
The Hausner’s ratio and the compressibility index were calculated 
for the applied stress of 4 kPa. Powders presenting the compressibility 
index of up to 25 are considered of acceptable flow properties (Aulton, 
1988; USP convention <> Powder Flow [Harmonization] USP 29/NF 
24, 1174). The Hausner’s ratio is related to the inter-particle friction and 
the powders with low inter-particle friction presenting the Hausner’s 
ratio of up to 1.35 are considered of acceptable flow properties (Aulton, 
1988; USP convention <> Powder Flow [Harmonization] USP 29/NF 
24, 1174). Therefore all the powders including MCC (PH102), 10% and 
20% loaded API-MCC composites exhibited acceptable flow properties, 
with an exception of 20% loaded CBZ-MCC composites which fall at the 
boundary of passable and poor flowing powders (in alignment with the 
data presented in Table 2 for compressibility index and Hausner’s ratio). 
Potentially this could be due to a large number of free CBZ nanoparticles 
in the CBZ-MCC composite, leading to an increase in compressibility 
index, Hausner’s ratio and poor flowability of the powder. 
The mechanical strength of pharmaceutical tablets is a bottleneck 
tablet property, as it impacts the pharmacokinetic and pharmacody-
namic behavior of the tablets (Michrafy et al., 2007; Wu et al., 2005). As 
mentioned in the introduction section, nanoparticles typically exhibit 
poor rheological properties. However, using the top spray dynamic bed 
coating process, the API nanoparticles presented optimal rheological 
properties. The mechanical strength of the tablets of the API-MCC 
Fig. 3. PXRD patterns for 10% loading and 20% loading samples of (A) CBZ (left), (B) RIS (middle), and (C) KET (right), isolated after the nanoparticle isolation 
experiment using top-spray dynamic bed coater. PXRD references for CBZ (FIII), RIS (Form B) and KET (FI) from Cambridge Structural Database (CSD) are presented 
in red and PXRD reference of as-received MCC is presented in Blue. 
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composites were examined by comparing their tabletability, compact-
ability and compressibility profiles. 
Tabletability is considered to be an ability of the powder to compress 
into a tablet with specific tensile strength. It is usually represented as a 
graph between tensile strength (MPa) versus compaction force (kN). 
Fig. 6 presents the tabletability profile of the tablets compressed for 10% 
and 20% loadings of API-MCC composites. The tensile strength of all the 
samples linearly increased with an increase in compaction force. MCC 
exhibited the highest tensile strength at the compaction force of 5kN, 
while the tensile strength of each isolated API-MCC composite was 
Fig. 4. SEM micrographs of 10% loading and 20% loading samples of carbamazepine (CBZ), risperidone (RIS) and ketoprofen (KET) onto microcrystalline cellulose 
(MCC) obtained using top-spray dynamic bed coating process. 
Fig. 5. Powder compressibility index of microcrystalline cellulose (MCC) (blue squares), 10% (left) and 20% (right) API- MCC composites. Red circle for carba-
mazepine (CBZ-MCC composite), black triangle for risperidone (RIS-MCC composite) and green rhombus for ketoprofen (KET-MCC composite) with n ≥ 3, n is the 
number of experiments. Each colour section represents a different powder flow behaviour. 
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nearly half of the MCC. MCC is an easily compressible material with 
excellent tensile strength that has been extensively studied and reported 
in the literature (Pudasaini et al., 2017). Though the tensile strength of 
the API-MCC composite are lower than that of MCC, it is still considered 
good as the tensile strength is above 2 MPa at high compression force of 
4 kN and above. A tensile strength value of>2 MPa is an essential 
requirement of the tablets for acceptable manufacturability, quality and 
biopharmaceutical performance (Chen et al., 2019). The tabletability 
parameter for each isolated solid was obtained using a linear regression. 
The slope of each line is an indicative parameter of the tabletability (Cp), 
presented in Table 3. MCC exhibited the highest value of Cp which is 1.5, 
while the 10% and 20% API-MCC composite samples presented a value 
of Cp close to 1.0, signifying slightly poor tabletability of API-MCC 
composite compared to MCC. 
Fig. 7 presents a graph of the tensile strength of MCC and each API- 
MCC composite samples as a function of porosity, to assess the com-
pactability of the 10% and 20% API-MCC composite samples. 
Compactability of a powder relates the powder plastic deformation and 
its ability to reduce volume under applied pressure. Further, Ryshke-
witch –Duckworth equation (Barralet et al., 2002) was used to analyse 
the compactability of all samples. The fitted parameters are presented in 
Table 3. The tensile strength at zero porosity (σt0) for all 10% and 20% 
loaded API-MCC composite samples is higher than that of MCC. The only 
outlier is the 10% loaded KET-MCC sample with a σt0 is 8.48, which 
could be potentially due to larger nanoparticle sizes agglomerated 
together, thereby introducing larger porosity to the system. Moreover, a 
higher b (constant) value is an indication of bonding capacity, repre-
senting a stronger bonding between the primary particles (Steendam 
and Lerk, 1998). MCC presents the lowest b value compared to the 10% 
and 20% API nanoparticles loaded MCC, corresponding to a lower ten-
dency of the MCC particles to interact with each other. On the contrary, 
a uniform API nanoparticle coating onto MCC particles increases the 
cohesive interactions between the API-MCC particles leading to a higher 
b Value. This data also supported by the SEM micrographs in Fig. 4 
which show a uniform coverage of the API nanoparticles onto the MCC 
particles. 
Fig. 8 presents the compressibility results of the 10% and 20% loaded 
API-MCC composites, showing the plot of –ln(Porosity) as a function of 
compaction force. The compressibility was analyzed using the Heckel 
equation. The Heckel coefficient, K (slope of the Heckel plot) and inverse 
value of yield pressure, Py; are presented in Table 3. MCC presents good 
plasticity and high compressibility properties based on its high Heckel 
coefficient and low yield pressure. On the contrary, 10% loading sam-
ples exhibit the inverse behavior than of pure MCC due to their low 
Heckel coefficient and high yield pressure, thereby presenting poor 
plasticity and low compressibility properties. Whereas, 20% loading 
samples presented improved compressibility compared to 10% loading 
sample but not as efficient as pure MCC. 
Fig. 9 presents the dissolution profile of each of the 10% and 20% 
Table 2 
Powder compressibility parameters, compressibility index (in %) and Hausner’s 
ratio for 10% and 20% API-MCC composite powder along with MCC (PH102) 
powder compressed at applied stress of 4 kPa; SD: standard deviation.  
Loading Sample Powder compressibility 
Average compressibility index (%) 
± SD 
Average Hausner’s ratio 
± SD  
MCC 16.8 ± 1.1 1.2 ± 0.02 
10% CBZ 20.9 ± 2.8 1.3 ± 0.04 
RIS 13.5 ± 0.6 1.2 ± 0.01 
KET 10.8 ± 1.5 1.1 ± 0.02 
20% CBZ 26.2 ± 2.9 1.4 ± 0.05 
RIS 19.3 ± 1.3 1.2 ± 0.02 
KET 15.6 ± 2.2 1.2 ± 0.03  
Fig. 6. Tabletability profile of the tablets prepared using microcrystalline cellulose (MCC) (blue squares), 10% (left) and 20% (right) API-MCC composites. Red circle 
for carbamazepine (CBZ-MCC composite), black triangle for risperidone (RIS-MCC composite) and green rhombus for ketoprofen (KET-MCC composite) with n ≥ 3, n 
is the number of experiments. 
Table 3 
Parameters derived through curve fitting of tensile strength vs compaction pressure for tabletability, from Ryskewitch-Duckworth equation for compactibitlity and 
Heckel coefficient for compressibility, for 10% and 20% API nanoparticle loaded MCC particles; Cp is Tabletability parameter, σt0 is tablet tensile strength at zero 
porosity (MPa), b is empirical constant, k is Heckle coefficient, Py is yield pressure.  
Loading Sample Tabletability Compactability Compressibility 
Cp R2 σt0 (MPa) -b R2 k Py (kN) R2  
MCC  1.5  0.99  11.25  6.1  0.91  0.42  2.36  0.87 
10% CBZ  0.99  0.99  17.88  8.3  0.97  0.23  4.37  0.97 
RIS  1.0  0.97  12.96  7.9  0.90  0.21  4.74  0.62 
KET  1.1  0.99  8.48  8.5  0.95  0.33  3.02  0.91 
20% CBZ  1.02  0.99  11.58  8.8  0.92  0.28  3.58  0.77 
RIS  1.5  0.99  15.84  8.4  0.97  0.34  2.97  0.93 
KET  1.1  0.99  15.97  9.6  0.96  0.30  3.35  0.96  
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loaded API-MCC composite powder comparing with the dissolution of 
the corresponding physical mixture samples of as-received API. The 
dissolution of CBZ nanoparticles was enhanced by 3–4 times as 
compared to the pure CBZ at 5 min, while dissolution of KET nano-
particle was only enhanced by 2–3 times compared to pure KET. The 
dissolution rate of KET is itself high for a BCS class II drug, therefore 
nanoparticles of KET influenced the dissolution to a smaller extent 
compared to CBZ and RIS. Further, the addition of SDS with CBZ for-
mulations could also potentially increase the dissolution rate of CBZ 
nanoparticles, as was observed for nanoparticle formulations of the 
Fig. 7. Compactability profile of the tablets prepared using microcrystalline cellulose (MCC) (blue squares), 10% (left) and 20% (right) API-MCC composites. Red 
circle for carbamazepine (CBZ-MCC composite), black triangle for risperidone (RIS-MCC composite) and green rhombus for ketoprofen (KET-MCC composite) with n 
≥ 3, n is the number of experiments. 
Fig. 8. Compressibility profile of the tablets prepared using microcrystalline cellulose (MCC) (blue squares), 10% (left) and 20% (right) API- MCC composites. Red 
circle for carbamazepine (CBZ-MCC composite), black triangle for risperidone (RIS-MCC composite) and green rhombus for ketoprofen (KET-MCC composite) with n 
≥ 3, n is the number of experiments. 
Fig. 9. Dissolution profiles of 10% loading and 20% loading of carbamazepine (CBZ) (CBZ + SDS + MCC, filled red triangles), risperidone (RIS) (RIS + MCC, filled 
green squares) and ketoprofen (KET) (KET + MCC, filled blue circles) obtained using top-spray dynamic bed coater, along with the dissolution profiles of physical 
mixtures of as-received CBZ (CBZ + SDS + MCC_PhyMix, hollow red traingles), RIS (RIS + MCC_PhyMix, hollow green squares) and KET (KET + MCC_PhyMix, 
hollow blue circles) with MCC. Curve fitting achieved using Korsmeyer-Peppas model is presented with dotted lines using the respective colors. Dissolution con-
ditions: PHARMATEST PTWS 120D dissolution test system, USP type II (paddle) apparatus. 900 mL, 37 ± 1◦C, 100 rpm, [CBMZ]max = 20.0 mg/L, [RIS]max = 15.0 
mg/L, [KET]max = 20.0 mg/L, n ≥ 3. 
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other APIs documented in the literature (Madelung et al., 2017; Rahman 
et al., 2020). The as-received CBZ dissolution in the presence of 10% SDS 
(as in the formulations) was doubled in first 5 min compared to the 
dissolution of CBZ-as received without SDS, as shown in Figure S1. 
Indeed, the dissolution enhancement of CBZ in the formulations could 
be potentially due to the presence of both SDS and the nano-sized CBZ 
particles. 
A major enhancement in the dissolution was observed for RIS. The 
dissolution of RIS nanoparticles was enhanced by 6–7 times compared to 
the pure RIS. The enhancement in RIS dissolution is based on two fac-
tors, firstly, nanoparticles of RIS dissolving at a higher rate than the as- 
received RIS, and secondly, due to the metastable polymorph (Form B) 
of RIS which itself is faster dissolving compared to its stable form (Form 
A). 
Further, the drug release curves were fitted using the Korsmeyer- 
Peppas model, which is useful for the study of drug release from poly-
meric systems. According to the Korsmeyer-Peppas model, the drug 
release rate constant of 20% loading API samples is approximately 10% 
higher compared to 10% loading samples, as presented in Table 4. 
Further, the drug release constant (n) value for all the samples obtained 
using the top-spray dynamic bed coater is less than the threshold for the 
Korsmeyer-Peppas (n = 0.43) (Peppas, 1985). Hence, the nanoparticles 
generated using top spray dynamic bed coating process help to enhance 
the dissolution rates of the poorly soluble APIs by following a diffusion 
controlled release mechanism. 
4. Conclusions 
The ‘top spray dynamic bed coater’ was successfully operated to 
produce nanoparticles of ketoprofen (KET), carbamazepine (CBZ) and 
risperidone (RIS), and coat them onto micron-sized MCC particles with 
10% and 20% theoretical drug loading. The average size of the API 
nanoparticles produced was in the range of 90–490 nm with high pro-
cessing yields of 49–90%. PXRD analysis confirmed the production of 
crystalline nanoparticles which were coated onto MCC particles with 
stable polymorphic forms for CBZ and KET, while metastable form for 
RIS. The Scanning Electron Microscopy (SEM) micrographs confirmed 
the uniform coating of API nanoparticles onto the MCC particles. The 
isolated API-MCC samples presented optimal rheological properties 
which were confirmed from the tabletability, compactibility and 
compressibility data analysis. Further, a 6–7 fold increase in the disso-
lution rate of RIS nanoparticles was observed, while 3–4 fold increase for 
CBZ nanoparticles and 2–3 fold increase for KET nanoparticles. The drug 
release rate of 20% loading samples is at least 10% higher compared to 
10% loading samples. Hence, top spray dynamic bed coating using su-
percritical CO2 as the atomizing gas is a novel method which provides a 
single-step approach to produce and isolate solid nanoparticles with 
optimal dissolution and rheological properties. 
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